Amounts Available for Obligation ¹
(Dollars in Thousands)

Source of Funding	FY 2011 Actual	FY 2012 Enacted	FY 2013 PB
Appropriation	539,082	536,801	535,610
Type 1 Diabetes	0	0	0
Rescission	(4,733)	(1,015)	0
Supplemental	0	0	0
Subtotal, adjusted appropriation	534,349	535,786	535,610
Real transfer under Secretary's transfer authority	0	(153)	0
Comparative Transfers for NCATS reorganization	0	0	0
Comparative Transfers to NCATS for Therapeutics and Rare and Neglected Diseases (TRND)	(440)	0	0
Comparative transfers to NLM for NCBI and Public Access	(459)	(485)	0
Subtotal, adjusted budget authority	533,450	535,148	535,610
Unobligated balance, start of year	0	0	0
Unobligated balance, end of year	0	0	0
Subtotal, adjusted budget authority	533,450	535,148	535,610
Unobligated balance lapsing	(89)	0	0
Total obligations	533,361	535,148	535,610

(Dollars in Thousands)
Budget Mechanism - Total 1/

MECHANISM	FY 2011 Actual		FY 2012 Enacted		FY 2013 PB		Change vs. FY 2012
Research Grants:	No.	Amount	No.	Amount	No.	Amount	No.	Amount
Research Projects:
Noncompeting	775	$261,350	754	$268,987	714	$255,049	(40)	($13,938)
Administrative Supplements	19	1,242	19	1,242	19	1,242	0	0
Competing:
Renewal	42	18,872	51	17,118	58	19,502	7	2,384
New	184	57,162	154	51,851	177	59,141	23	7,290
Supplements	2	928	2	845	3	955	1	110
Competing	228	$76,962	207	$69,814	238	$79,598	31	$9,784
Subtotal, RPGs	1,003	$339,554	961	$340,043	952	$335,889	(9)	($4,154)
SBIR/STTR	27	$12,572	27	$13,345	27	$13,791	0	$446
Research Project Grants	1,030	$352,126	988	$353,388	979	$349,680	(9)	($3,708)
Research Centers:
Specialized/Comprehensive	40	$41,578	40	$41,578	40	$41,576	0	($2)
Clinical Research	0	0	0	0	0	0	0	0
Biotechnology	0	0	0	0	0	0	0	0
Comparative Medicine	0	29	0	29	0	29	0	0
Research Centers in Minority Institutions	0	0	0	0	0	0	0	0
Research Centers	40	$41,607	40	$41,607	40	$41,605	0	($2)
Other Research:
Research Careers	155	$19,480	155	$19,480	155	$19,479	0	($1)
Cancer Education	0	0	0	0	0	0	0	0
Cooperative Clinical Research	0	0	0	0	0	0	0	0
Biomedical Research Support	0	0	0	0	0	0	0	0
Minority Biomedical Research Support	0	0	1	264	1	264	0	0
Other	29	3,146	29	3,146	28	3,146	(1)	0
Other Research	184	$22,626	185	$22,890	184	$22,889	(1)	($1)
Total Research Grants	1,254	$416,359	1,213	$417,885	1,203	$414,174	(10)	($3,711)
Research Training:	FTTPs		FTTPs		FTTPs
Individual Awards	63	$3,121	62	$3,121	61	$3,121	(1)	$0
Institutional Awards	249	12,551	245	12,551	241	12,550	(4)	(1)
Total Research Training	312	$15,672	307	$15,672	302	$15,671	(5)	($1)
Research & Development Contracts	51	$19,195	51	$19,456	51	$23,630	0	$4,174
SBIR/STTR	0	$19	0	$19	0	$19	0	$0
	FTEs		FTEs		FTEs		FTEs
Intramural Research	129	$54,438	129	$54,438	128	$54,438	(1)	$0
Research Management and Support	105	27,786	105	27,697	104	27,697	(1)	0
Construction		0		0		0		0
Buildings and Facilities		0		0		0		0
Total, NIAMS	234	$533,450	234	$535,148	232	$535,610	(2)	$462

Summary of Changes
(Dollars in Thousands)

FY 2012 Enacted				$535,148
FY 2013 President's Budget				$535,610
Net change				$462
	2013 President's Budget		Change from FY 2012
CHANGES	FTEs	Budget Authority	FTEs	Budget Authority
A.Built-in:
1. Intramural Research:
a. Annualization of January 2012 pay increase & benefits		$17,685		$1
b. January FY 2013 pay increase & benefits		17,685		54
c. One more day of pay		17,685		68
d. Annualization of PY net hires		17,685		0
e. Payment for centrally furnished services		9,502		0
f. Increased cost of laboratory supplies, materials, other expenses, and non-recurring costs		27,251		0
Subtotal				$123
2. Research Management and Support:
a. Annualization of January 2012 pay increase & benefits		$14,562		$1
b. January FY 2013 pay increase & benefits		14,562		45
c. One more day of pay		14,562		56
d. Annualization of PY net hires		14,562		0
e. Payment for centrally furnished services		4,695		0
f. Increased cost of laboratory supplies, materials, other expenses, and non-recurring costs		8,440		0
Subtotal				$102
Subtotal, Built-in				$225

Summary of Changes - continued

	2013 President's Budget		Change from FY2012
CHANGES	No.	Amount	No.	Amount
B. Program:
1. Research Project Grants:
a. Noncompeting	714	$256,291	(40)	($13,938)
b. Competing	238	79,598	31	9,784
c. SBIR/STTR	27	13,791	0	446
Total	979	$349,680	(9)	($3,708)
2. Research Centers	40	$41,605	0	($2)
3. Other Research	184	22,889	(1)	(1)
4. Research Training	302	15,671	(5)	(1)
5. Research and development contracts	51	23,630	0	4,174
Subtotal, Extramural		$453,475		$462
	FTEs		FTEs
6. Intramural Research	128	$54,438	(1)	($123)
7. Research Management and Support	104	27,697	(1)	(102)
8. Construction		0		0
9. Buildings and Facilities		0		0
Subtotal, program	232	$535,610	(2)	$237
Total changes				$462

Top

Fiscal Year 2013 Budget Graphs

History of Budget Authority and FTEs:

Distribution by Mechanism:

Change by Selected Mechanisms:

Top

Budget Authority by Activity

1. Includes FTEs which are reimbursed from the NIH Common Fund.
2. Includes Real Transfers and Comparable Adjustments as detailed in the "Amounts Available for Obligation" table.

Top

Authorizing Legislation

Top

Appropriations History

Top

Justification of Budget Request

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Authorizing Legislation: Section 301 and title IV of the Public Health Service Act, as amended.

Top

DIRECTOR'S OVERVIEW

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a broad range of research, training, and information dissemination activities related to bone, joint, muscle, and skin diseases. Some are rare disorders, many are common. All have a major impact on the quality of people’s lives. Conditions addressed by NIAMS affect individuals of all ages, of all racial and ethnic backgrounds, and across all economic strata. Many disproportionately affect women and minorities. Over the years, NIAMS-funded research teams have made significant progress in uncovering the causes and improving the treatment of many disorders. The primary Federal agency for conducting and supporting medical research into conditions of the bone, joint, muscle, and skin, NIAMS manages a portfolio that addresses immediate public health needs, while encouraging basic science research that may lead to improved health. Its efforts fill a void in our Nation's research and development pipeline by supporting studies that the commercial sector would not pursue because they may not be immediately profitable. As described below, many NIAMS activities and plans directly relate to the four themes of the NIH Director’s Extraordinary Opportunities for FY 2013.

Theme 1: Investing in Basic Research
Much of the NIAMS budget supports basic research into the biological processes underlying health and disease. Many of these studies require investigators to grow specific types of cells in their laboratories. Over the past five years, researchers have been using or developing techniques to convert a relatively new type of stem cell, inducible pluripotent stem (iPS) cells, into different cell types for their experiments. This has provided opportunities for studying melanocytes (the cells that make freckles, cause tanning, or mutate to produce melanoma), and other skin cells or muscle cells that can be used to study disease-causing mutations.

Other basic research efforts are raising the possibility that existing medications might be useful treatments for additional diseases. Researchers studying a model of lupus nephritis, a severe form of systemic lupus erythematosus (SLE), recently discovered that activation of a certain type of immune cell damaged the animals’ kidneys. This insight, combined with an understanding of the basic mechanisms by which the asthma drug omalizumab prevents inflammation, prompted the team to plan a study of whether the drug is safe for people who have SLE.

Theme 2: Accelerating Discovery through Technology
Tissue engineering relies on technological advances that enable scientists to use cells, scaffolds, and biologically active molecules to produce healthy, functional tissues or organs. Recently, researchers have made progress toward being able to grow skin for people with a debilitating and life-threatening skin disease called recessive dystrophic epidermolysis bullosa (RDEB). They isolated cells from patients, corrected the molecular defect, and grew the modified cells into sheets of tissue that they transplanted onto mice. After successfully transplanting the modified skin on mice, they were able to quickly launch a clinical trial of adults affected by RDEB.

NIAMS also invests heavily in the development of imaging tools for studies or diagnosis of a variety of diseases and conditions. Some NIAMS investigators are developing x-ray techniques and computer algorithms to better assess a person’s risk of fracture, with the goal of enabling physicians to better determine which patients require treatment. Others are testing magnetic resonance imaging strategies to examine muscle or joint tissue. One group is exploring the utility of two office-based tests—electrical impedance myography and quantitative ultrasound—for quick, painless monitoring of people with muscle diseases who are participating in clinical trials.

NIAMS-funded researchers also are developing methods to deliver drugs to patients in clinical studies and, ultimately, in clinical care. One group is creating a microneedle injection system that they can use to test a potential treatment for people who have pachyonychia congenita, an ultra-rare skin disorder that manifests as painful calluses and blisters on the soles of the feet. Although the therapy showed promise in an earlier trial funded through the NIAMS Small Business Innovation Research (SBIR) program, the pain associated with the original injection system prompted the investigators to pursue a method that is more patient-friendly.

Theme 3: Advancing Translational Sciences
As NIAMS looks toward FY 2013, it is exploring ways to help researchers optimize small molecule drugs for the treatment of inflammatory and chronic degenerative diseases, such as rheumatoid arthritis (see example in the Intramural Research Program, below). In 2011, NIAMS funded its first grants under a new effort to support smaller and shorter studies on which larger clinical trials could be based. In addition to encouraging the research community to translate basic research findings and animal studies into clinical trials, NIAMS also supports efforts to verify preliminary clinical observations with larger studies. Recently, researchers demonstrated that teriparatide, a parathyroid hormone derivative already approved for older women who have osteoporosis, restored cartilage in mouse joints that resembled the knees of post-traumatic osteoarthritis (OA) patients. This finding is a classic example of how clinical observations can inform basic research questions: the researchers designed their animal studies after colleagues noted that people who had OA and were taking parathyroid hormone for osteoporosis had less arthritis pain. If subsequent studies show that teriparatide has a favorable risk-benefit profile and stimulates cartilage regeneration in patients, it would be the first disease-reversing drug to be available for the millions of Americans who are plagued by OA.

Theme 4: Encouraging New Investigators and New Ideas
NIAMS uses a combination of institutional training grants and individual fellowships to ensure a continuing supply of well-trained scientists prepared to conduct cutting-edge research related to musculoskeletal, skin, and rheumatic diseases. At the NIH Clinical Center, the NIH Rheumatology Fellowship Training Program, which NIAMS leads, is dedicated to the clinical and research training of physicians who wish to pursue careers in biomedical or translational research related to rheumatic diseases. The program is accredited by the Accreditation Council for Graduate Medical Education (ACGME), and graduates are eligible to undergo the certifying examination in the subspecialty of rheumatology.

To encourage promising new researchers around the country to study arthritis and musculoskeletal and skin diseases and injuries, NIAMS offers a grant program specifically for investigators who have not previously been funded by the NIH. The NIAMS Small Grant Program for New Investigators provides successful applicants with up to three years of funding to develop the pilot data that would make them competitive for a full, independent project.

Overall Budget Policy: The FY 2013 President’s Budget request for NIAMS is $535.610 million or 0.09 percent over the FY 2012 Enacted level. Investigator-initiated research project grants and research conducted by new scientists continue to be the Institute’s highest priorities. As part of this effort, NIAMS is committed to training and supporting a diverse biomedical research community that will continue to make advances for generations to come.

Top

Program Descriptions and Accomplishments

Arthritis and Rheumatic Diseases: The goals of this program are to advance high-quality basic, translational, and clinical biomedical and biopsychosocial research to treat, cure, and prevent inflammatory arthritis and other rheumatic diseases. It utilizes new insights in the fields of genetics, genomics, proteomics, immunology, and imaging to understand how the immune system interacts with various tissues in normal and pathological conditions and to ensure a continuous supply of new targets on which therapies can be based. Scleroderma, one of the rheumatic diseases within the NIAMS mission, was a main topic at the Institute’s 2011 scientific planning retreat, as an increasing number of discoveries related to the immune system’s role in the disease are providing new research opportunities related to potential therapeutic targets (see Program Portrait: Studies of the Immune Response Reveal Link with Fibrosis). In FY 2011, NIAMS awarded a new five-year Center for Research Translation (CORT) grant to conduct multidisciplinary research to better understand systemic sclerosis, a form of scleroderma affecting multiple organ systems. The Institute also funded a new CORT to uncover genetic and environmental factors contributing to Sjögren’s syndrome, an autoimmune disease in which a person’s disease-fighting cells attack the glands that produce tears and saliva, as well as other tissues. As part of its FY 2012 planning process, NIAMS conducted a roundtable discussion with approximately a dozen arthritis biology researchers. At the meeting, participants discussed basic and translational research opportunities that might lead to promising therapies for diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis.

Budget Policy: The FY 2013 President’s Budget request for this program is $115.618 million, an increase of $0.119 million or 0.10 percent over the FY 2012 Enacted level. In FY 2013, NIAMS will continue to support genome-wide association studies and in-depth follow-up analyses in rheumatic diseases, such as SLE and juvenile idiopathic arthritis. These studies will provide insights into genetic risk for these conditions, and identify potential therapeutic targets. In follow-up to a FY 2011 roundtable discussion on the early warning signs of autoimmune diseases, the Institute will encourage research into fundamental pathologic processes that might lead to strategies to impede or arrest disease progression. Ongoing efforts to use existing resources from large clinical projects to further understand disease mechanisms also will continue.

Musculoskeletal Biology and Diseases: This program focuses on understanding the fundamental biology of tissues that constitute the musculoskeletal system, and on translating and applying this knowledge to a variety of diseases and conditions including osteoarthritis (OA). It funds research on the causes and treatment of acute and chronic injuries, including repetitive stress and sports injuries, and is supporting a long-term study into the effectiveness of various treatments for patients who have low back pain. Some of its grants are comparing surgical approaches to repairing torn knee ligaments, suggesting how existing surgical techniques could be improved, or examining conditioning regimens that may protect young female athletes from knee injuries. The program also supports the development of technologies—such as bone and joint imaging, tissue engineering, and regenerative medicine—to improve the diagnosis and treatment of skeletal disorders, or to facilitate repair of damage caused by trauma to otherwise healthy tissue. In FY 2011, NIAMS funded a new five-year effort to translate some of these cutting-edge imaging strategies into clinical tools that will enhance disease management and outcomes in people with OA.

Budget Policy: The FY 2013 President’s Budget request for this program is $124.280 million, an increase of $0.126 million or 0.10 percent over the FY 2012 Enacted level. Program plans for FY 2013 include encouraging research into the risk factors for and the pathophysiology of OA, with the goal of advancing the development and testing of interventions for OA. As a leader of the Osteoarthritis Initiative (OAI), a public-private partnership to create a resource that any researcher can use to identify and evaluate OA markers, NIAMS intends to intensify its efforts to educate members of the research community about the availability and potential utility of OAI clinical data and images that can complement or provide a basis for their research. Other activities include partnering with the National Institute on Aging on an effort to solicit grant applications to explore the mechanisms of OA that develop during aging.

Bone Biology and Diseases: The program covers a broad spectrum of research designed to better understand the build-up and break down of bone. It supports studies of the genetic and cellular mechanisms involved in regulating bone remodeling and bone formation, resorption, and mineralization processes, and the effects of hormones, growth factors, and cytokines on bone cells and on other organ systems (see Program Portrait: Integrative Physiology of Bone and Muscle, below). It oversees several large epidemiologic cohorts to characterize the development and progression of osteoporosis, and for identification of genetic and environmental risk factors that contribute to fractures. Through the Bone Biology and Diseases Program, the Institute leads the Federal Working Group on Bone Diseases—an interagency committee that offers a forum for sharing information and facilitating the development of collaborative bone research activities based on each agency's mission. Recent working group topics have included NIH collaborations with the military to understand severe bone problems that impair the recovery of people who have been injured by improvised explosive devices; evidence linking viruses to Paget’s disease of bone; and emerging findings that are influencing the labeling and prescribing of osteoporosis drugs.

Budget Policy: The FY 2013 President’s Budget request for this program is $72.057 million, an increase of $0.073 million or 0.10 percent over the FY 2012 Enacted level. NIAMS recognizes the unprecedented opportunities that genome-wide association studies hold for identifying genetic changes that influence bone health. The discovery of genetic variants that protect against osteoporosis or increase a person’s risk of having low bone mass is likely to suggest targets for the development of drugs that prevent fragility fractures. Moreover, investigators could use genetic markers to identify appropriate participants for clinical trials. Institute plans for FY 2013 include encouraging exploration in this area by advertising the availability of a new genetic database for musculoskeletal disorders, funded by the American Recovery and Reinvestment Act.

Muscle Biology and Diseases: This program supports a wide range of basic, translational, and clinical research projects in skeletal muscle biology and diseases. It focuses on the fundamental biology of muscle development, muscle physiology, and muscle imaging. Its overarching objective is to explain the role that muscle plays in health and, ultimately, to treat or prevent skeletal muscle diseases and disorders, including muscular dystrophies, inflammatory myopathies, muscle ion channel diseases, disuse atrophy, skeletal muscle injury, and loss of muscle mass associated with aging and diseases. As part of its FY 2011 scientific planning process, the Institute organized a discussion on how it might capitalize on the burgeoning number of basic discoveries that could potentially be translated into therapies for people who have muscle diseases. In this same vein, the NIAMS-funded researchers are preparing to launch a clinical trial for people who have limb-girdle muscular dystrophy.

Budget Policy: The FY 2013 President’s Budget request for this program is $72.820 million, an increase of $0.075 million or 0.10 percent over the FY 2012 Enacted level. For FY 2013, the Institute will continue to participate in the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers Program. It will continue to support a Center for Research Translation grant to assess a strategy to repair the genetic defect that causes Duchenne muscular dystrophy. The Center is focusing on a series of small molecules that target different disease causing mutations, with the goal of developing drugs that health care providers could choose from based on an individual’s genetic information. Other plans include fostering research into the role skeletal muscle plays in influencing the health of other organ systems (see Program Portrait: Understanding of Bone and Muscle Interactions Moves Beyond Locomotion, above).

Skin Biology and Diseases: This program supports a broad portfolio of basic, translational, and clinical research in skin, including work on the developmental and molecular biology of skin, the study of skin as an immune organ, and the genetics of skin diseases. The Institute is pursuing opportunities in developing tools for skin regeneration, and imaging technologies for diagnosis and tracking progression of skin diseases. The 2011 NIAMS scientific planning retreat had a session on research advances and opportunities of the innate immune system—the body’s first line of defense against infectious agents in skin (see Program Portrait: Studies of the Immune Response Reveal Link with Fibrosis, above). New avenues of research that are ripe for investigation include the impact of methicillin-resistant Staphylococcus aureus (MRSA) infections on skin, as well as the effect of the skin’s commensal bacteria on MRSA infections. The Institute held a roundtable discussion in FY 2012 on the research needs, challenges, and opportunities in pediatric dermatology, and in related diseases such as atopic dermatitis (eczema), alopecia areata, rare genetic diseases (e.g., epidermolysis bullosa, ichthyoses), and acne. NIAMS continued its support in FY 2011 for the development of a multi-institutional and multidisciplinary research network to evaluate treatments for psoriasis across a large population.

Budget Policy: The FY 2013 President’s Budget request for this program is $68.700 million, an increase of $0.069 million or 0.10 percent over the FY 2012 Enacted level. In FY 2013, NIAMS will continue to support skin research into the effects of chemicals from accidents or terrorist attacks, toward the development of potential countermeasures. NIAMS will fund ongoing studies on the molecular and cellular factors regulating skin and hair follicle development and regeneration, which can also inform regenerative medicine efforts in other organ systems. The Institute will also encourage further investigation on the role of immune system genes in skin diseases, based on findings from genome-wide association studies. This knowledge can augment NIAMS’s standing research program in skin immunology and autoimmunity, to facilitate translation of laboratory findings to clinical care.

Intramural Research Program: The program’s mission is to conduct innovative basic, translational, and clinical research relevant to the health concerns of the Institute, and to provide training for investigators who are interested in related research careers. Scientists perform clinical studies on the genetics, etiology, pathogenesis, and treatment of a variety of rheumatic, autoimmune, inflammatory, joint, skin, and muscle diseases. The program has recently expanded its research and training capacity by establishing a Laboratory of Regenerative Medicine and a Laboratory of Oral Connective Tissue Biology. The addition of these two accomplished research teams will spur collaborations with fields that complement the expertise of the NIAMS researchers. Meanwhile, ongoing partnerships within and outside of NIH continue. In collaboration with researchers around the world, the NIAMS scientists are exploring large genetic databases that provide insights into the immune-system defects that underlie rare inflammatory diseases such as ankylosing spondylitis (a progressive arthritis affecting the spine). Others are working closely with the private sector to move their fundamental discoveries into clinical trials. For example, an intramural investigator’s discovery of an immune system protein led to the identification of therapeutic targets for several rheumatic conditions. As a result of this advance and subsequent work facilitated by two Cooperative Research and Development Agreements (CRADAs) between NIH and industry, a new drug is in clinical trials and may be available to rheumatoid arthritis patients by the end of 2012.

Budget Policy: The FY 2013 President’s Budget request for this program is $54.438 million, the same as the FY 2012 Enacted level. NIAMS plans for FY 2013 include maintaining its focus on translational research, in order to facilitate patient-oriented studies in the areas of arthritis, musculoskeletal, and skin diseases, including their genetic, inflammatory, and immune underpinnings. NIAMS will also continue its multidisciplinary training of rheumatology research fellows, giving them a foundation in biomedical research and experience in treating patients with diverse rheumatic diseases in a real-life community healthcare setting (see Program Portrait: The NIAMS Community Health Center). The Institute's intramural research program anticipates enhancing its recent collaborative scientific and programmatic activities throughout its portfolio. This effort mimics the continued research partnerships that NIAMS scientists have with experts around the world, including those in private industry, which have led to fundamental insights into the genetics and mechanisms of disease, and helped identify new targets for novel treatments and interventions.

Top

Research Management and Support (RMS): The RMS program supports the scientific, administrative management, and information technology activities associated with day-to-day operations. In FY 2011, the Institute managed more than 1,254 research grants and centers, as well as 51 research and development contracts and 312 individual and institutional full-time research training positions. NIAMS funded 508 clinical research studies, including 61 clinical trials. In FY 2011, the Institute hosted the NIAMS 25th Anniversary Scientific Symposium: Improving Lives Through Discovery. The meeting brought together a broad array of senior and early-stage NIAMS-supported investigators, whose descriptions of research advances and promising new areas of exploration were complemented by personal stories from patients who are challenged by arthritis, musculoskeletal, and skin diseases. As evidence of its continued commitment to information dissemination, the newly redesigned NIAMS webpage scored among the top ranked federal websites in a national survey of customer satisfaction. In addition, the Institute’s use of social media has grown significantly, marked by the development of a widely utilized Twitter account that has been used to highlight research advances, Institute events, and new materials for the public.

Budget Policy: The FY 2013 President’s Budget request for this program is $27.697 million, the same as the FY 2012 level. In FY 2013, NIAMS will continue its efforts to improve access to, and availability of, meaningful health information for racial and ethnic minority populations through its Multicultural Outreach Initiative (MCOI). Using feedback from MCOI focus groups, NIAMS is developing resources for patients and the public in the form of "health planners" that people can use to organize medical appointments and other health-related activities. Soon, community partners will assess the effectiveness of these materials through field testing, which will help NIAMS refine the products and create an electronic toolkit that partner organizations can use to customize the materials. The Institute also will continue to sponsor roundtable discussions and a scientific retreat with extramural investigators and lay representatives to inform the research priority-setting and strategic planning process.

Top

Budget Authority by Object

Includes FTEs which are reimbursed from the NIH Common Fund.

Top

Salaries and Expenses

Top

Details of Full-Time Equivalent Employment (FTEs)

Top

Detail of Positions